疼痛（Pain）治療薬の世界市場：画期的医薬品の市場機会及び商用化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Figures 3
2 Executive Summary 4
2.1 Large and Innovative Pipeline 4
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents 4
2.3 Active Deals landscape with Numerous Investment Oppertunities 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.1.1 Chronic and Neuropathic Pain 10
4.1.2 Disease Pathophysiology 11
4.1.3 Diagnosis 14
4.1.4 Treatment Option 15
4.1.5 Treatment Algorithm 16
4.2 Overview of Marketed Products for Pain 17
4.2.1 Analgesic Product Categories 17
4.2.2 Molecular Type Analysis 19
4.2.3 Molecular Target Analysis 20
4.2.4 Current Unmet Needs 22
5 Assessment of Pipeline Product Innovation 23
5.1 Pain Pipeline by Molecule Type, Phase and Therapeutic Targets 23
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family 27
5.3 First-in-Class Pipeline Programs 29
5.4 First-in-Class Targets by Pain Subtype 31
6 Pain Patent Analysis 34
7 First-in-Class Target and Pipeline Program Evaluation 43
7.1 Pipeline Programs Targeting Fatty Acid Amide Hydrolase 43
7.2 Pipeline Programs Targeting Purinoceptor 3 45
7.3 Pipeline Programs Targeting Purinoceptor 7 48
7.4 Pipeline Programs Targeting Purinoceptor 4 50
7.5 Pipeline Programs Targeting Orexin Receptor Type 1 51
7.6 Pipeline Programs Targeting Neuronal Nitric Oxide Synthase 53
7.7 Pipeline Programs that Target Tropomyosin-Related Kinase A 55
7.8 Pipeline Programs that Target C-C Chemokine Receptor 2 59
7.9 Pipeline Programs that Target Endomorphin 2 61
7.10 Pipeline Programs that Target Protein Kinase Cγ 63
7.11 Pipeline Programs that Target Opioid Receptor-Like-1 Receptor 65
7.12 Pipeline Programs that Target Bradykinin B1 Receptor 69
7.13 Pipeline Programs Targeting Galanin Receptor 2 73
7.14 Pipeline Programs Targeting Nerve Growth Factor 76
8 Deals and Strategic Consolidations 80
8.1 Industry Industry-wide First-in-Class Deals 80
8.2 Pain Deals Landscape 81
8.3 Licensing Deals 82
8.3.1 Molecule Type 84
8.3.2 Mechanism of Action 85
8.4 Co-development Deals 90
8.4.1 Molecule Type 91
8.4.2 Mechanism of Action 92
8.5 First-in-Class Programs Not Involved in Licensing or Co-Development Deals 96
9 Appendix 98
9.1 Abbreviations 98
9.2 References 99
9.3 Contact Us 106
9.4 Disclaimer 106